UBS Downgrades Intra-Cellular Therapies to Neutral, Lowers Price Target to $83
UBS Downgrades Intra-Cellular Therapies to Neutral, Lowers Price Target to $83
瑞銀將intra-cellular therapies評級下調至中立，將目標價格下調至83美元。
UBS analyst Ashwani Verma downgrades Intra-Cellular Therapies (NASDAQ:ITCI) from Buy to Neutral and lowers the price target from $85 to $83.
瑞銀分析師Ashwani Verma將納斯達克股票交易代碼ITCI的intra-cellular therapies評級從買入下調至中立，並將目標價從85美元降至83美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。